pirarubicin

Also Known As:

4'-O-tetrahydropyranyladriamycin; 4'-O-tetrahydropyranyldoxorubicin; 4'-O-tetrapyranyldoxorubicin; THP-ADM; THP-DOX; THP-adriamycin; THP-doxorubicin; Theprubicin; Théprubicine; pirarubicin hydrochloride; thepirubicin; therarubicin; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-

Networked: 550 relevant articles (66 outcomes, 109 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fang, Jun: 15 articles (05/2022 - 01/2005)
2.	Maeda, Hiroshi: 13 articles (07/2021 - 01/2005)
3.	Hara, Takeshi: 8 articles (10/2018 - 02/2004)
4.	Tsurumi, Hisashi: 8 articles (10/2018 - 02/2004)
5.	Etrych, Tomáš: 7 articles (04/2022 - 02/2015)
6.	Nakamura, Hideaki: 7 articles (01/2020 - 01/2014)
7.	Takami, Tsuyoshi: 7 articles (10/2018 - 02/2004)
8.	Chytil, Petr: 6 articles (01/2020 - 01/2014)
9.	Coronnello, Marcella: 6 articles (06/2019 - 02/2009)
10.	Dei, Silvia: 6 articles (06/2019 - 02/2009)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2012 - "To analyze the influence of intravesical Pirarubicin (THP) instillation on the prediction results of European Organization for Research and Treatment of Cancer (EORTC) risk tables and to discuss the efficacy of EORTC risk tables in clinical application. " 01/01/2018 - "In conclusion, the results in our study demonstrated that RIPK1 inhibition enhances the anti-tumor effect of pirarubicin by overcoming drug resistance. " 11/01/2013 - "This study conducted further analysis of the Pirarubicin Monotherapy Study Group cohort, focusing on intravesical seeding of cancer cells. " 11/15/1990 - "A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors. " 10/01/1985 - "[Phase II study of 4'-O-tetrahydropyranyl-adriamycin (THP-ADM) in patients with gynecological cancer]."
2.	Non-Muscle Invasive Bladder Neoplasms 01/01/2020 - "Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer." 03/01/2021 - "This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer. " 06/05/2020 - "This study will explore whether or not pirarubicin can be used as an effective and safety treatment for patients with NMIBC. " 06/05/2020 - "This study will provide a synthesis of current evidence to investigate the efficacy and safety of pirarubicin for NMIBC using overall survival, progression-free survival, recurrence-free survival, quality of, rates of recurrence, and adverse events. " 06/05/2020 - "All randomized controlled trials of pirarubicin for NMIBC will be included regardless limitations related to the language and publication time. "
3.	Breast Neoplasms (Breast Cancer) 06/01/1990 - "Thirty-four patients with metastatic breast cancer were treated in a multicenter phase II study with pirarubicin (THP) using a dosage of 75 mg/m2/every 3 weeks. " 06/01/1990 - "Phase II study of pirarubicin in metastatic breast cancer." 05/01/1990 - "In summary, the early results of this trial suggest that pirarubicin is an active and rather well tolerated drug in pretreated patients with advanced breast cancer." 05/01/1990 - "In a phase II study, 77 patients with metastatic breast cancer were treated with pirarubicin, 70 mg/m2 iv every 3 weeks. " 01/01/1990 - "Pirarubicin in advanced breast cancer: a French cooperative phase II study."
4.	Carcinoma (Carcinomatosis) 11/01/2010 - "Improved detection of nonmuscle invasive urothelial carcinoma of the bladder using pirarubicin endoscopy: a prospective, single-center preliminary study." 09/15/1992 - "Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma." 09/15/1992 - "A Phase II trial of Pirarubicin was done in 26 patients who had not previously had chemotherapy and who had measurable and incurable head and neck carcinoma. " 11/01/1992 - "Twenty one patients with either metastatic or inoperable locally advanced bladder carcinoma were treated with intravenous infusion of pirarubicin: 25 mg/m2/day for 3 days every 4 weeks in the first 15 patients and 20 mg/m2/day for 3 days every 3 weeks in the others. " 11/01/2013 - "The Pirarubicin Monotherapy Study Group trial was a randomized Phase II study that evaluated the efficacy of intravesical instillation of pirarubicin in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. "
5.	Cardiotoxicity 01/01/2019 - "Protective Effects of Apocynum venetum Against Pirarubicin-Induced Cardiotoxicity." 05/01/1992 - "Pirarubicin (PIRA) has been shown to have improved potency with less cardiac toxicity in several phase I and II clinical trials in Japan and Europe. " 10/13/2023 - "Pirarubicin (THP) is an antitumour drug widely used in clinical practice, but its cardiotoxicity limits its application. " 01/01/2022 - "The cardiotoxicity of pirarubicin (THP) seriously affects its clinical application, which cannot be ignored. " 01/01/2017 - "We investigated the potential protective effect of rutinum (RUT) against pirarubicin- (THP-) induced cardiotoxicity. "

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Vincristine (Oncovin)
3.	Cyclophosphamide (Cytoxan)
4.	Cisplatin (Platino)
5.	pirarubicin
6.	Epirubicin (Ellence)
7.	Prednisolone (Predate)
8.	Anthracyclines
9.	Fluorouracil (Carac)
10.	Etoposide (VP 16)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intravesical Administration
3.	Therapeutics
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Nephroureterectomy